John is a health content expert and wellness researcher with a passion for preventative medicine and holistic lifestyle habits. Known for his ability to make intricate health topics easy to digest, John focuses on providing scientifically grounded insights that help readers take control of their long-term well-being. When he isn't researching the latest in clinical wellness, he is exploring the intersection of technology and human performance.
Novartis discontinues its FSHD muscular dystrophy drug, ladademirsen, after the AOC therapy failed to meet primary endpoints in a Phase 2 clinical trial.
CAMP4 Therapeutics plans to launch a genetic disorder clinical trial in the UK by late 2026, leveraging novel RNA-targeting technology for precision therapy.
Medicus Pharma announces positive Phase 2 results for SkinJect®, a non-surgical treatment for basal cell carcinoma. Read the latest clinical trial update.
Clinical trial access for bladder cancer remains unequal. Expert María Natalia Gandur Quiroga discusses the urgent need to bridge regional research gaps.
A new Phase 1/2 clinical trial for OPGx-BEST1 reveals promising safety and efficacy results for patients with inherited retinal diseases. Learn more here.
Labcorp strengthens its global clinical trial capacity by acquiring MLM Medical Labs, aiming to accelerate drug development and biomarker research worldwide.